Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer

[1]  G. Hanna,et al.  Surgeon Volume and Cancer Esophagectomy, Gastrectomy, and Pancreatectomy: A Population-based Study in England , 2016, Annals of surgery.

[2]  J. Søreide,et al.  Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer , 2016, Molecular oncology.

[3]  H. Ueno,et al.  Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer , 2015, Scientific Reports.

[4]  N. Malats,et al.  Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer , 2015, BMC Cancer.

[5]  T. H. Santa Rita,et al.  EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. , 2015, Clinical biochemistry.

[6]  Katherine Van Loon,et al.  Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. , 2015, Cancer discovery.

[7]  E. Ma,et al.  Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments , 2015, Proceedings of the National Academy of Sciences.

[8]  G. Capurso,et al.  Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. , 2015, World journal of gastrointestinal endoscopy.

[9]  R. Scharpf,et al.  Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients , 2015, Nature Communications.

[10]  K. Nouso,et al.  Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer , 2015, Cancer.

[11]  K. Lillemoe,et al.  Circulating Tumor Cells Found in Patients With Localized and Advanced Pancreatic Cancer , 2015, Pancreas.

[12]  François-Clément Bidard,et al.  High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection. , 2015, Lab on a chip.

[13]  K. Nouso,et al.  761 Detection of K-RAS Gene Mutation by Liquid Biopsy in Patients With Pancreatic Cancer , 2015 .

[14]  I. Bièche,et al.  Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.

[15]  M. Erlander,et al.  Comparative circulating tumor DNA levels for KRAS mutations in patients with nonresectable pancreatic cancer. , 2015 .

[16]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[17]  M. Braga,et al.  Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer , 2015, Tumor Biology.

[18]  V. Bobek,et al.  Circulating tumor cells in pancreatic cancer patients: enrichment and cultivation. , 2014, World journal of gastroenterology.

[19]  Ben S. Wittner,et al.  Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells , 2014, Cell reports.

[20]  W. Weichert,et al.  KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma , 2014, Pancreas.

[21]  Timothy B Lannin,et al.  Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. , 2014, Lab on a chip.

[22]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[23]  Timothy B Lannin,et al.  Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. , 2014, Gastroenterology.

[24]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[26]  Steven A. Soper,et al.  Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma , 2014, PloS one.

[27]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[28]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[29]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[30]  F. Bidard,et al.  Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  D. Goldstein,et al.  Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Lillemoe,et al.  Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection? , 2013, Annals of surgery.

[33]  Sridhar Ramaswamy,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.

[34]  S. Mulvihill,et al.  Screening for Pancreatic Cancer: Why, How, and Who? , 2013, Annals of surgery.

[35]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[36]  V. Servois,et al.  Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma , 2012, Clinical Cancer Research.

[37]  Sridhar Ramaswamy,et al.  RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis , 2012, Nature.

[38]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[39]  Peter Kuhn,et al.  Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors , 2012, Physical biology.

[40]  Sepp Kaul,et al.  Multimarker Gene Analysis of Circulating Tumor Cells in Pancreatic Cancer Patients: A Feasibility Study , 2012, Oncology.

[41]  L Khoja,et al.  A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker , 2011, British Journal of Cancer.

[42]  Xiaohang Zhao,et al.  Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy , 2011, Cancer biology & therapy.

[43]  Richard O Hynes,et al.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. , 2011, Cancer cell.

[44]  K. Kinzler,et al.  Detection and quantification of rare mutations with massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[45]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[46]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[47]  Mohid S. Khan,et al.  Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors , 2011, Clinical Cancer Research.

[48]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[49]  T. Roskams,et al.  Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma , 2011, BMC Cancer.

[50]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[51]  Z. Meng,et al.  K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[52]  J. Jacob,et al.  Clinical utility of circulating tumor cell measurement in the diagnosis of indeterminate lesions of the pancreas. , 2010, Future oncology.

[53]  H. Oettle,et al.  Follow-Up Study of K-ras Mutations in the Plasma of Patients With Pancreatic Cancer: Correlation With Clinical Features and Carbohydrate Antigen 19-9 , 2009, Pancreas.

[54]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. McCarter,et al.  Results of a Phase I Trial of 12 Patients With Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation: Report of Toxicity and Evaluation of Circulating K-ras as a Potential Biomarker of Response to Therapy , 2009, American journal of clinical oncology.

[56]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[57]  K. Pantel,et al.  Detection and Monitoring of Cell‐Free DNA in Blood of Patients with Colorectal Cancer , 2008, Annals of the New York Academy of Sciences.

[58]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  F. Itokawa,et al.  Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. , 2008, Journal of hepato-biliary-pancreatic surgery.

[60]  M. Nagino,et al.  Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). , 2008, Japanese journal of clinical oncology.

[61]  W. Scheithauer,et al.  CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. , 2008, The Lancet. Oncology.

[62]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[63]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[64]  J. Thiery,et al.  Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. , 2007, World journal of gastroenterology.

[65]  M. Fleischhacker,et al.  Circulating nucleic acids (CNAs) and cancer--a survey. , 2007, Biochimica et Biophysica Acta.

[66]  H. Kalthoff,et al.  Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival , 2005, Journal of Cancer Research and Clinical Oncology.

[67]  R. Hruban,et al.  Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion , 2005, Modern Pathology.

[68]  Chen,et al.  A Prospective Study of Kras Mutations in the Plasma of Pancreatic Cancer Patients 1 , 2005 .

[69]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[70]  R. Swaminathan,et al.  Role of Cell‐Free Plasma DNA as a Diagnostic Marker for Prostate Cancer , 2004, Annals of the New York Academy of Sciences.

[71]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[72]  又木 雄弘.  Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during follow-up period of patients who underwent curative surgery for biliary-pancreatic cancer : Longitudinal analyses , 2004 .

[73]  A. Nakao,et al.  Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients , 2003, Journal of Gastroenterology.

[74]  J. Yu,et al.  A Prospective Study of Detection of Pancreatic Carcinoma by Combined Plasma K -ras Mutations and Serum CA19-9 Analysis , 2002, Pancreas.

[75]  P. Ruszniewski,et al.  Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA , 2002, British Journal of Cancer.

[76]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[77]  J. Werner,et al.  Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. , 2001, Surgery.

[78]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[79]  T. Okai,et al.  K‐ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma , 1999, Cancer.

[80]  J. Müller,et al.  K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis , 1999, Langenbeck's Archives of Surgery.

[81]  G. Capellá,et al.  K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  J. Malagelada,et al.  Vagaries of clinical presentation of pancreatic and biliary tract cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[84]  J. Parma,et al.  Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. , 1998, Gastrointestinal endoscopy.

[85]  M Monden,et al.  Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  M. Farthing,et al.  A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  R. Hruban,et al.  K‐ras mutations in the duodenal fluid of patients with pancreatic carcinoma , 1998, Cancer.

[88]  J. Furuse,et al.  CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. , 1997, Hepato-gastroenterology.

[89]  R. Hruban,et al.  Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. , 1994, Cancer research.

[90]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[91]  P. Rothberg,et al.  Oncogenes and cancer. , 1983, Cancer investigation.

[92]  Kochi,et al.  Detection of Kras mutations in the plasma DNA of pancreatic cancer patients , 2022 .